Science & Societal Blog
/ CDMO, Formulation Development, Oral Solid Dosage

Insights on Maximizing Late-Stage Success through Early CMC Strategies

3 Minute Read

Adapted from the webinar, Early CMC Strategies to Support Late Stage Success, featuring Societal™ CDMO SMEs Neha Shah, Director of Product Development, and Kiran Pedada, Director of Analytical Development, hosted by Contract Pharma.

To Begin

In the changing landscape of pharmaceutical development, the process from early-stage research to late-stage success is made up of endless complexities. Undoubtedly vital to this journey is the CMC aspect, which plays a pivotal role in ensuring the safety, efficacy, and quality of pharmaceutical products. To walk you through the key pieces of the puzzle, you are invited to read the following adaptation of a webinar hosted by Contract Pharma featuring Societal’s own Neha Shah, Director of Product Development, and Kiran Pedada, Director of Analytical Development. Our experts share the importance of proactive CMC planning and its impact on overall drug development outcomes.


The goal of achieving late-stage success is captured in the details of your process. Effective CMC planning should commence as early as the preclinical stages, allowing for a seamless transition through clinical development phases. By making certain considerations in the earliest stages of drug development, you begin to mitigate risk, optimize processes, and ultimately expedite regulatory approvals. Below are key takeaways from the webinar:

1. Risk Assessment and Mitigation: Comprehensive risk assessments early in the development process enable proactive mitigation strategies, minimizing delays and setbacks during late-stage development.

2. Quality by Design (QbD) Approach: Implementing a QbD approach facilitates systematic evaluation and optimization of product quality attributes throughout the development lifecycle, streamlining development and ensuring regulatory compliance.

3. Regulatory Compliance and Expedited Approvals: Early engagement with regulatory authorities fosters smoother approval processes, as open communication channels allow companies to seek guidance and address concerns proactively.

4. Technology Adoption and Innovation: Embracing technological advancements and innovative approaches drive efficiency and differentiation in CMC strategies, empowering companies to stay competitive and agile.

5. Flexibility and Adaptability: Individuals with the right mindset demonstrate a keen sense of flexibility and adaptability, recognizing the dynamic landscape of formulation and analytical development. At Societal CDMO, we tailor strategies and approaches to address the ever-changing challenges and seize emerging opportunities.

Our team’s readiness to adapt guarantees responsiveness to project demands, enabling us to efficiently navigate unexpected hurdles. In doing so, we significantly enhance the prospects of success for drug development endeavors.

In Closing

By prioritizing the aforementioned considerations, companies can enhance the efficiency, quality, and speed of their drug development programs. It should not be taken for granted the time and excess spending that can be incurred due to a less than detailed approach. As the landscape continues to evolve, leveraging these strategies early on will remain instrumental in reaching successful development outcomes.

To learn more and view the webinar in full, click here [link to webinar].

Neha Shah, Ph.D.
Director of Product Development
Follow Neha Shah, Ph.D. on LinkedIn